The disclosure also contemplates the use of one or more of the formulations or compositions, in the manufacture of medicaments for treating, abating, reducing, or ameliorating the symptoms of a disease, dysfunction, or disorder in a mammal, such as a human that has, is suspected of having, or at risk for developing an auris interna disorder
[11] [12] Tirzepatide (Mounjaro) a dual GIP/GLP-1 receptor agonist approved in the UK for type 2 diabetes and for weight management
Shared decision-making should address realistic expectations, as tirzepatide addresses metabolic and weight management aspects but does not treat the underlying autoimmune thyroid condition
Nonoxidative ethanol metabolism in humans-from biomarkers to bioactive lipids
Common digestive effects include: Nausea (reported in approximately 15-20% of patients according to the SmPC) Vomiting Diarrhoea Constipation Abdominal discomfort or bloating These symptoms typically emerge during dose initiation or escalation and often improve over several weeks as the body adapts